Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01774526|
Recruitment Status : Unknown
Verified December 2012 by National University Hospital, Singapore.
Recruitment status was: Recruiting
First Posted : January 24, 2013
Last Update Posted : January 24, 2013
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Other: Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes||Not Applicable|
Lung cancer is a malignant disease of heterogeneous histology and is divided into 2 major groups; small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for 75% of lung cancers, and can exhibit different pathways of resistance during treatment. It is increasingly apparent that effective treatment of NSCLC will require multiple drugs that attack different targets. This realization sets the stage for future individualized therapies that will depend on the molecular characteristics of NSCLC to target various pathways.
- Describe the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotype.
- Correlate tumor molecular characteristics with patient demographics and outcome to better understand carcinogenesis as well as in the discovery of novel targets for future drug development.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2016|
- Descriptive study of our patients with lung adenocarcinoma. Identify novel molecular characteristics so that potential drug development can be reached. [ Time Frame: 6 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01774526
|Contact: Pyng Lee, MDfirstname.lastname@example.org|
|National University Hospital/ National University of Singapore||Recruiting|
|Contact: Pyng Lee, MD +65-67795555 email@example.com|
|Principal Investigator:||Pyng Lee, MD||National University Hospital, Singapore|